



INDIAN COUNCIL OF MEDICAL RESEARCH

Department of Health Research - Ministry of Health & Family Welfare Government of India

Rapid methods for antimicrobial susceptibility testing at point-of-care

Development of novel and/or improved diagnostic methods are sought to reduce the inappropriate and blind prescription of antibiotics and consumption with appropriate guidance and monitoring. We are aware that your research group has developed a point-of-care (POC) diagnostic which identify and facilitate the detection of drug resistant pathogens. ICMR is conducting a survey to understand the landscape of available indigenous diagnostics and efforts carried by scientist or private companies. This survey is meant to identify bottleneck or other challenges that are impeding the availability of good quality diagnostics in our health care system. Through this questionnaire we are seeking the information about developed diagnostic for antimicrobial susceptibility testing at POC and its validation.

eveloped diagnostic for antimicrobial susceptibility testing at POC and its validation.		
1.	What type of diagnostic/ assay/ method/ product is developed?	
2.	What is the intended use or application of the diagnostic?	
3.	Please provide the information of developer (s).	
4.	What is the principle (technology) of developed diagnostic?	
5.	Please describe the novelty of diagnostic.	

6. What will be the beneficiary groups for the diagnostic? (e.g. POC, healthcare level, clinicians, nurses, hospital management, staff, patients, educationalists/socialist, technology experts and developers, local government and policy makers etc.)

	What is the stage of development of diagnostic? (e.g. Proof of concept or objective evidence)			
	Whether there was any association for the development of diagnostic	on or partnership with industry or govern?	nmental orgai	nization
	□No □Yes, Please s	pecify		
	Whether any accreditation or mark	c or approval is obtained for the develope	ed diagnostic?	
	□ No □ Yes, Please sp	pecify		
10.	(Examples: For Instrument: ins. Performance qualification (PQ), e For assay: protocol, specimen	performed (process of qualification)? tallation qualification (IQ), Operational quipment details, service and maintenant and antibiotics panel details, sample alification, comparisons with alternati	ce e design, sta	atistical
	Specimen used			
	Targeted pathogen (s)			
	Antibiotics panel used			
	Testing population, sample size and design			
	Gold standard or Reference followed or comparison (method currently or previously in use) used			
	Parameter of validation met	Sensitivity (true positive)	□ No	□Yes
		Specificity (true negative)	□ No	□Yes
		Positive predictive value (PPV)	□ No	□Yes
		Negative predictive value (NPV)	□ No	<u> Yes</u>
		uncertainty of measurement (UM)	□ No	Yes
		Limit of detection(LOD)	□ No	Yes
		Precision	□ No	<u> </u>
		Linearity	□ No	Yes
		Accuracy	□ No	Yes
		Reproducibility (Robustness) Analytical sensitivity and specificity	□ No □ No	☐ Yes ☐ Yes
		Limit of quantitation (LOQ)	□ No	☐ Yes
		Any Other, if any	LI NO	<u> </u>
	Results Turnaround time	This other, it any		
	How many tasts can be marfarmed	4		
	How many tests can be performe (minimum & maximum) in a standard six hour working shift?	u		
	I Standard SIA HOUL WOLKING SHILL			

11.

12.

13.

14.

Stability/ shelf life tested	□ No □ Yes, please specify					
Any cross or collaborator laboratory test validation	□ No □ Yes, please specify					
Quality control parameters met						
Is there any test results available for samples which challenge the performance of the method?	□ No □ Yes, please specify					
Any IPR/copyright issues worth mentioning?						
Limitation, if any						
Is developed diagnostic available in (e.g. published, controlled distribution). Whether cost benefit analysis done of	on, patent etc.)					
Whether associated risk assessment evaluated or not? (e.g. any risk of new procedure or additional hazards arise throughout the course of the evaluation which were not identified during the initial risk assessment?)						
Any other information related to you	Any other information related to your developed diagnostic, you wish to provide.					
	Name:					
	Designation:					
	Date:					
	Signature:					